λ² νλ€μ½
**λ² νλ€μ½(Bethanechol)**μ ν©μ± μ½λ¦° μμ€ν λ₯΄μ΄μ μ§μ μμ©νλ λΆκ΅κ°μ κ²½ ν₯λΆμ (μ½λ¦°μ± μ½λ¬Ό)μ λλ€. - **μ£Όμ μμνμ μ©λ**: μ£Όλ‘ μλλ¬Όμ λ°©κ΄ μμΆμ μκ·Ήνλ λ° μ¬μ©λλ©°, **λ°°λ¨κ·Ό 무λ ₯μ¦**(μ΄μλκ³ κ³Όλνκ² ν½μ°½λμ΄ μ λλ‘ μμΆνμ§ λͺ»νλ λ°©κ΄) μΉλ£μ κ°μ₯ μ°μ μ μΌλ‘ μ¬μ©λλ μ½λ¬Όμ λλ€. μ΄λ μ’ μ’ μ¬κ°ν λ°©κ΄ κ³Όν½μ°½μ΄λ μ κ²½κ³ μ§ν(μ: νμ μ΄λ μ κ²½μ λ³λ³)μ μ΄μ°¨μ μΌλ‘ λ°μν©λλ€. - **μμμ μ§μ£Ό(Clinical Pearl)**: λ°©κ΄ μμΆμ μκ·ΉνκΈ° μ μ μλ κ΄μ½κ·Όμ΄ μ΄μλμ΄ μλμ§ νμΈνλ κ²μ΄ λ§€μ° μ€μν©λλ€. λ°λΌμ λ°©κ΄ νμ΄μ λ°©μ§νκΈ° μν΄ μν-1 κΈΈνμ (μ: νλΌμ‘°μ λλ νλ Ήμλ²€μλ―Ό) λλ 골격근 μ΄μμ (μ: λμμ ν)μ ν¨κ» μ²λ°©λλ κ²½μ°κ° λ§μ΅λλ€. - **μμ₯κ΄ μ©λ**: κ³Όκ±°μλ μλ λλ μΌλ°μ μΈ μμ₯κ΄ μκ·Ήμ λ‘ μ¬μ©λμμΌλ, νμ¬ μ΄λ¬ν μ©λλ λλΆλΆ λ©ν ν΄λ‘νλΌλ―Έλμ λ€μ€μ€ν°κ·Έλ―ΌμΌλ‘ λ체λμμ΅λλ€. - **μ½λ¦¬νμ νΉμ§**: μμΈνΈμ½λ¦°μμ€ν λΌμμ μ μν κ°μλΆν΄μ λν μ νμ±μ΄ λ§€μ° λμ μ²μ° μμΈνΈμ½λ¦°μ λΉν΄ μμ© μκ°μ΄ νμ ν κΉλλ€.
μμ© κΈ°μ : Bethanechol directly stimulates **muscarinic (M) cholinergic receptors**, with a strong affinity for the **M3 receptors** located on the smooth muscle of the detrusor (bladder wall) and gastrointestinal tract. - **Mechanism Pathway**: Binds to M3 receptor β activates Gq-protein β stimulates Phospholipase C (PLC) β increases Inositol triphosphate (IP3) and Diacylglycerol (DAG) β triggers release of intracellular calcium (Ca2+) β **smooth muscle contraction**. - **Receptor Specificity**: At usual therapeutic doses, it has negligible effects on nicotinic receptors, which minimizes skeletal muscle and ganglionic side effects. - **Physiological Effects**: Increases detrusor muscle tone, decreases bladder capacity, increases GI peristalsis, and increases gastric/pancreatic secretions.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Bladder neck or urinary outflow obstruction
- Questionable bladder wall integrity (e.g., recent bladder surgery)
- Hyperthyroidism
- Peptic ulcer disease or inflammatory GI lesions
- Recent GI surgery with resections/anastomoses
- GI obstruction or peritonitis
- Hypersensitivity to bethanechol
- Epilepsy
- Asthma
- Coronary artery disease or occlusion
- Hypotension
- Severe bradycardia
- Vagotonia or vasomotor instability
μ΄μλ°μ
- Salivation
- Lacrimation
- Urination
- Defecation
- Vomiting
- Diarrhea
- Anorexia
- Bradycardia (high dose/SC)
- Arrhythmias (high dose/SC)
- Hypotension (high dose/SC)
- Asthma/Dyspnea (high dose/SC)
- Abdominal pain (horses)
μ½λ¬Ό μνΈμμ©
- Anticholinergic drugs (e.g., atropine, glycopyrrolate, propantheline) Β· Can antagonize bethanechol's effects
- Other cholinergic drugs Β· Additive toxicity and increased risk of cholinergic crisis Β· major
- Atropine Β· Antagonizes the effects of bethanechol Β· moderate
λͺ¨λν°λ§
- Clinical efficacy (successful urination, reduction in residual bladder volume)
- Signs of cholinergic toxicity (SLUD: salivation, lacrimation, urination, defecation)
- Heart rate and rhythm (if given parenterally)
κ³Όμ©λ
Clinical signs of overdosage are basically cholinergic in nature. - **Mild/Moderate Toxicity**: Muscarinic effects (salivation, urination, defecation, vomiting) are usually seen with oral or SC administration. - **Severe Toxicity**: If given IM or IV, a full-blown **cholinergic crisis** can occur, characterized by circulatory collapse, bloody diarrhea, shock, and possible cardiac arrest. - **Treatment**: **Atropine** is the specific antidote for bethanechol toxicity. Epinephrine may also be employed to treat clinical signs of severe bronchospasm.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.